Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Amortization of Deferred Charges (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $9794.0 as the latest value for Q4 2017.

  • Quarterly Amortization of Deferred Charges changed 0.02% to $9794.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $39177.0 through Dec 2017, down 28.76% year-over-year, with the annual reading at $21283.0 for FY2018, 45.67% down from the prior year.
  • Amortization of Deferred Charges for Q4 2017 was $9794.0 at Bone Biologics, roughly flat from $9795.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $25613.0 in Q1 2016, with the low at $9793.0 in Q3 2016.